Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial.
Quick navigation
Link to full study
http://www.ncbi.nlm.nih.gov/pubmed/30705687
Conclusion of this study
NC supplementation in overweight/obese NAFLD patients improved glucose indices, lipids, inflammation, WC, nesfatin, liver transaminases, and fatty liver degree. Accordingly, the proposed mechanism for ameliorating NAFLD with NC was approved by the increased serum nesfatin and likely consequent improvements in inflammation, lipids, and glucose profile. Further trials of nano-curcumin's effects are suggested.
Supplements analyzed in this study
|
Health conditions analyzed in this study
No health conditions information for this study.Functions related to this study
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
Body systems related to this study
Cardiovascular System |
Digestive System |
Endocrine System |
Immune System |